WATCH NOW: Natera/ISHLT Webinar on New Metrics for dd-cfDNA in Heart Transplant
On 24 September, Natera and ISHLT collaborated to host a webinar entitled “Two Thresholds, One Powerful Solution.” The webinar drew more than 180 registrations and the recording is now available to all.
Noninvasive monitoring for acute rejection with donor derived cell free DNA (dd-cfDNA) is a proven alternative to invasive surveillance biopsies. Until recently, dd-cfDNA tests have only reported dd-cfDNA as a fraction of total cell free DNA (dd-cfDNA %) in the circulation. This fraction can be confounded by fluctuations in the amount of total cell free DNA, sometimes caused by factors unrelated to the health of the allograft, including infection, surgery, or chemotherapy. Prospera™ Heart now incorporates a second metric—the Donor Quantity Score (DQS)—which is the estimated quantity of cell free DNA coming from the donated heart, and is independent of fluctuations in levels of total cell free DNA.
This webinar explores clinical implications of adding a second threshold to noninvasive monitoring for rejection. Suphamai Bunnapradist, MD, MS, a transplant nephrologist from UCLA, provides a unique perspective as a long-time user of this technology. Additionally, panelists Brent Lampert, DO, of the Ohio State University Wexner Medical Center, and Roopa Rao, MD, of Indiana University Health, discuss their first-hand experience with Prospera™ with DQS in heart transplantation. Hear their early accounts including relatable case reviews.
Watch now to learn how the addition of DQS significantly reduces the rate of false positive results and improves the accuracy of detecting both acute cellular rejection (ACR) and antibody mediated rejection (AMR).
